SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based inNorway , announces the completion of last subject last visit in a Phase 1 study of SIS-01 (NCT05188638). SIS-01 is a first-in-human study investigating the safety and tolerability of single and multiple doses of nebulised SoftOx Inhalation Solution (SIS) delivered via a jet nebuliser to healthy subjects. A total of 57 healthy volunteers were randomised to receive SIS or placebo. SoftOx is looking forward to announcing the top line results by the end of Q2 2022. "We are pleased to report the achievement of this import milestone. We are extremely grateful to our study participants andDanTrials ApS for helping us to complete the study according to plan," said DrChristopher Burton , Chief Medical Officer on the SIS project. "We anticipate that this study will provide evidence of a safety and tolerability profile suitable for progression to Phase 2 clinical development within various upper and lower respiratory tract infectious disease indications." SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological oxidant with broad spectrum antimicrobial (antiviral and antibacterial) properties. This randomized, double-blind trial is the first systematic, placebo-controlled, ascending dose study investigating the safety and tolerability of low concentrations of inhaled HOCl in humans. For further information, please contact: Geir Almås, CEO ofSoftOx Solutions AS , orChristopher Burton , CMO, SIS,SoftOx Solutions AS Mail: ir@soft-ox.com Phone: Front Desk: (+47) 948-59-599 AboutSoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biotech/medtech company based inOslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com
Click here for more information
© Oslo Bors ASA, source